Your browser doesn't support javascript.
loading
Genomic Spectrum and Phenotypic Heterogeneity of Human IL-21 Receptor Deficiency.
Cagdas, Deniz; Mayr, Daniel; Baris, Safa; Worley, Lisa; Langley, David B; Metin, Ayse; Aytekin, Elif Soyak; Atan, Raziye; Kasap, Nurhan; Bal, Sevgi Köstel; Dmytrus, Jasmin; Heredia, Raul Jimenez; Karasu, Gulsun; Torun, Selda Hancerli; Toyran, Muge; Karakoc-Aydiner, Elif; Christ, Daniel; Kuskonmaz, Baris; Uçkan-Çetinkaya, Duygu; Uner, Aysegul; Oberndorfer, Felicitas; Schiefer, Ana-Iris; Uzel, Gulbu; Deenick, Elissa K; Keller, Baerbel; Warnatz, Klaus; Neven, Bénédicte; Durandy, Anne; Sanal, Ozden; Ma, Cindy S; Özen, Ahmet; Stepensky, Polina; Tezcan, Ilhan; Boztug, Kaan; Tangye, Stuart G.
Afiliação
  • Cagdas D; Division of Pediatric Immunology, Department of Pediatrics, Ihsan Dogramaci Children's Hospital, Hacettepe University Medical Faculty, Ankara, Turkey. deniz.ayvaz@hacettepe.edu.tr.
  • Mayr D; Section of Pediatric Immunology, Institutes of Child Health, Health Science Institute, Hacettepe University, Ankara, Turkey. deniz.ayvaz@hacettepe.edu.tr.
  • Baris S; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
  • Worley L; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Langley DB; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Metin A; Department of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Aytekin ES; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
  • Atan R; The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
  • Kasap N; Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.
  • Bal SK; St Vincent's Clinical School, Faculty of Medicine, UNSW, Sydney, Australia.
  • Dmytrus J; St Vincent's Clinical School, Faculty of Medicine, UNSW, Sydney, Australia.
  • Heredia RJ; Department of Pediatric Immunology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
  • Karasu G; Division of Pediatric Immunology, Department of Pediatrics, Ihsan Dogramaci Children's Hospital, Hacettepe University Medical Faculty, Ankara, Turkey.
  • Torun SH; Department of Pediatrics, Hacettepe University Medical Faculty, 1031, Ankara, Turkey.
  • Toyran M; Department of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Karakoc-Aydiner E; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
  • Christ D; The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
  • Kuskonmaz B; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
  • Uçkan-Çetinkaya D; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Uner A; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Oberndorfer F; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
  • Schiefer AI; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Uzel G; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Deenick EK; Ludwig Boltzmann Institute for Rare and Undiagnosed Diseases, Vienna, Austria.
  • Keller B; St. Anna Children's Cancer Research Institute (CCRI), Vienna, Austria.
  • Warnatz K; CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences, Vienna, Austria.
  • Neven B; Department of Pediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
  • Durandy A; School of Medicine, Goztepe Medicalpark Hospital, Pediatric stem Cell Transplantation Unit, Istinye University, Istanbul, Turkey.
  • Sanal O; Istanbul Medical Faculty, Pediatric Infectious Disease, Istanbul University, Istanbul, Turkey.
  • Ma CS; Department of Pediatric Immunology, Ankara City Hospital, University of Health Sciences, Ankara, Turkey.
  • Özen A; Department of Pediatric Allergy and Immunology, Marmara University Faculty of Medicine, Istanbul, Turkey.
  • Stepensky P; Istanbul Jeffrey Modell Diagnostic and Research Center for Primary Immunodeficiencies, Istanbul, Turkey.
  • Tezcan I; The Isil Berat Barlan Center for Translational Medicine, Istanbul, Turkey.
  • Boztug K; Garvan Institute of Medical Research, 384 Victoria Street, Darlinghurst, NSW, 2010, Australia.
  • Tangye SG; St Vincent's Clinical School, Faculty of Medicine, UNSW, Sydney, Australia.
J Clin Immunol ; 41(6): 1272-1290, 2021 08.
Article em En | MEDLINE | ID: mdl-33929673
ABSTRACT
Biallelic inactivating mutations in IL21R causes a combined immunodeficiency that is often complicated by cryptosporidium infections. While eight IL-21R-deficient patients have been reported previously, the natural course, immune characteristics of disease, and response to hematopoietic stem cell transplantation (HSCT) remain to be comprehensively examined. In our study, we have collected clinical histories of 13 patients with IL-21R deficiency from eight families across seven centers worldwide, including five novel patients identified by exome or NGS panel sequencing. Eight unique mutations in IL21R were identified in these patients, including two novel mutations. Median age at disease onset was 2.5 years (0.5-7 years). The main clinical manifestations were recurrent bacterial (84.6%), fungal (46.2%), and viral (38.5%) infections; cryptosporidiosis-associated cholangitis (46.2%); and asthma (23.1%). Inflammatory skin diseases (15.3%) and recurrent anaphylaxis (7.9%) constitute novel phenotypes of this combined immunodeficiency. Most patients exhibited hypogammaglobulinemia and reduced proportions of memory B cells, circulating T follicular helper cells, MAIT cells and terminally differentiated NK cells. However, IgE levels were elevated in 50% of IL-21R-deficient patients. Overall survival following HSCT (6 patients, mean follow-up 1.8 year) was 33.3%, with pre-existing organ damage constituting a negative prognostic factor. Mortality of non-transplanted patients (n = 7) was 57.1%. Our detailed analysis of the largest cohort of IL-21R-deficient patients to date provides in-depth clinical, immunological and immunophenotypic features of these patients, thereby establishing critical non-redundant functions of IL-21/IL-21R signaling in lymphocyte differentiation, humoral immunity and host defense against infection, and mechanisms of disease pathogenesis due to IL-21R deficiency. Outcome following HSCT depends on prior chronic infections and organ damage, which should thus be considered as early as possible following molecular diagnosis.
Assuntos
Palavras-chave

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Subunidade alfa de Receptor de Interleucina-21 Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia

Texto completo: 1 Base de dados: MEDLINE Assunto principal: Subunidade alfa de Receptor de Interleucina-21 Idioma: En Ano de publicação: 2021 Tipo de documento: Article País de afiliação: Turquia